ElectroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 Entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
ElectroCore Expands Intellectual Property Portfolio With U.S. Patent No. 11,894,148 Entitled "Systems And Methods For Treating Patients With Diseases Associated With Viruses"
electroCore, Inc. (NASDAQ:ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated with viruses in the Coronaviridae family (COVID).
商業階段的生物電子醫學和健康公司ElectroCore, Inc.（納斯達克股票代碼：ECOR）今天宣佈，美國專利商標局已頒發了一項與治療冠狀病毒家族（COVID）病毒相關疾病的系統和方法相關的專利。
U.S. Patent No. 11,894,148 entitled "Systems and Methods for Treating Patients With Diseases Associated With Viruses" generally relates to methods for treating disorders with viruses in the COVID family using electrical impulses transcutaneously to the vagus nerve for about 30 seconds to about 5 minutes, from 2 to 5 times per day, to reduce a level of C-reactive protein in the blood of the patient.
美國第11,894,148號專利，題爲 “治療與病毒相關的疾病的患者的系統和方法”，通常涉及使用經皮電脈衝迷走神經約30秒至約5分鐘，每天2至5次，以降低患者血液中C反應蛋白水平的方法治療COVID家族中的病毒疾病。